Hims wasn’t stepping back enough from its practice of mass marketing compounded versions of the weight-loss medicine, said ...

The calming in the oil market came as several analysts said Iran would likely refrain from closing the waterway. Iran itself ...

U.S. stocks are drifting, and oil prices are flip-flopping following the United States’ bunker-busting entry into Israel’s ...

Trump’s tariffs and the trade war continue to affect global markets as the Israel-Iran conflict unfolds. Follow along for live updates on the Dow, S&P 500 and Nasdaq.

U.S. pharma companies should pay rather more of their corporate income tax in the U.S.—and start producing more of their best drugs in the U.S. as well.

Novo Nordisk (NVO) closed at $69.72 in the latest trading session, marking a -5.49% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.96%. Elsewhere, the Dow ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 ...

Shares of Hims & Hers Health plunged by more than 30% after Danish weight-control drug maker Novo Nordisk abruptly pulled out of a partnership with the telehealth firm on the distribution of Wegovy.

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...